JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Papadimos, T. J.
Right arrow Articles by Rush, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Papadimos, T. J.
Right arrow Articles by Rush, J. E.
Related Collections
Right arrow Monitoring (Non-cardiac)
Right arrow Pharmacology

Anesth Analg 2004;98:548-549
© 2004 International Anesthesia Research Society
doi: 10.1213/01.ANE.0000097172.44227.0D


GENERAL ARTICLES

A Suspected Case of Delayed Onset Malignant Hyperthermia with Desflurane Anesthesia

Thomas J. Papadimos, MD MPH, Mohamad Almasri, MD, James C. Padgett, CRNA BS, and Joanne E. Rush, CRNA MS

Department of Anesthesiology, Medical College of Ohio, St. Luke’s Hospital Heart Center, Maumee

Address correspondence and reprint requests to Thomas J. Papadimos, MD, 7162 Copperwood Lane, Sylvania, Ohio 43560. Address e-mail to TPapadimos{at}mac.com

Desflurane has been identified as a weak triggering anesthetic of malignant hyperthermia that, in the absence of succinylcholine, may produce a delayed onset of symptoms. The prolonged interval after exposure may occur more than 6 h after the induction of anesthesia. The unintended underdosing of this patient with dantrolene and the prompt reversal of symptoms may be an attribute of the genetic expression of a weak triggering volatile anesthetic such as desflurane.

IMPLICATIONS: There are multiple genetic variations for malignant hyperthermia (MH) at the ryanodine receptor. Desflurane, as a sole trigger of MH, is weak, and on two occasions in the literature (including this case), less than optimal doses of dantrolene were given with a good result. There may be possible to engineer the risk of MH out of an anesthetic once the genetics of the ryanodine receptor are better understood.




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
L. Stemp, T. J. Papadimos, I. Sen, D. Thapa, and K. K. Gombar
Interpretation of PO2 via FIO2 * Response * Response
Anesth. Analg., September 1, 2004; 99(3): 955 - 955.
[Full Text] [PDF]




Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2004 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2004 by the International Anesthesia Research Society.